← ANALYST RATINGS · TIPRANKS
SAB Biotherapeutics (SABS): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $12.67, the highest $15.00, the lowest $10.00. The average is +400.7% from the last price of $2.53.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Sell | −1.2% | Downgrade | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | +18.6% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | +18.6% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | +18.6% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | +18.6% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | +18.6% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 | Hold | +38.3% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 | Hold | +38.3% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 | Hold | +38.3% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 | Hold | +18.6% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 | Hold | +38.3% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 | Hold | +38.3% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| Unknown Analyst | Guggenheim | $15.00 | Buy | +492.9% | Reiterated | 07.08.26on TipRanks Aug 14 21:05 | +0.7%next day −3.0% · 5 days −5.5% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $13.00 | Buy | +413.8% | Reiterated | 07.08.26on TipRanks 04:17 | +0.7%next day −3.0% · 5 days −5.5% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $10.00 | Buy | +295.3% | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +2.3%next day +0.7% · 5 days −3.8% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $14.00 → $16.00+14.3% | Buy | +532.4% | Reiterated | 16.06.26on TipRanks 22:13 | +6.7%next day +2.6% · 5 days +0.9% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | $6.00 | Buy | +137.2% | Reiterated | 16.06.26on TipRanks 09:15 | −5.6%next day +6.7% · 5 days +6.9% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $11.00 | Buy | +334.8% | Reiterated | 15.06.26on TipRanks Jun 16 05:45 | +15.4%next day −5.6% · 5 days +1.8% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $14.00 | Buy | +453.4% | Reiterated | 15.06.26on TipRanks 07:50 | +15.4%next day −5.6% · 5 days +1.8% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $11.00 | Buy | +334.8% | Initiated | 20.05.26on TipRanks 04:55 | +2.6%next day +3.3% · 5 days −4.8% | ↗ |
| Seema Sheoran★★★★★★★★★★#8280 · hits 33% · avg +0.9% | Rodman & Renshaw | $13.00 | Buy | +413.8% | Initiated | 02.04.26on TipRanks Apr 14 09:11 | +0.2%next day −1.2% · 5 days −7.0% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $7.00 | Buy | +176.7% | Reiterated | 25.02.26on TipRanks Feb 26 08:15 | +4.2%next day +5.6% · 5 days +1.2% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | — | Buy | — | Reiterated | 21.10.25on TipRanks Oct 22 06:15 | 0.0%next day +0.5% · 5 days −1.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering SAB Biotherapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.67 at a price of $3.17 (+299.6%); now: $12.67 at $2.53 (+400.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 15 | 11 | 9 | 3 | 3 |
| Buy | 2 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.28 (from $-0.32 to $-0.16). Last quarter: $-0.28.
Best top-analyst consensus in the sector · Healthcare
About SAB Biotherapeutics
- CEO: Samuel J. Reich
- Employees: 86
- 777 W 41st St., Miami Beach, FL, 33140, US
- www.sab.bio
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Data from the stock’s TipRanks forecast page, read 111 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗